SUPERNUS PHARMACEUTICALS INC's ticker is and the CUSIP is 868459AD0. A total of 43 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $343,438 | +1.0% | 350,000 | 0.0% | 0.00% | – |
| Q3 2022 | $340,000 | +0.3% | 350,000 | 0.0% | 0.00% | – |
| Q2 2022 | $339,000 | -2.0% | 350,000 | 0.0% | 0.00% | – |
| Q1 2022 | $346,000 | -0.6% | 350,000 | 0.0% | 0.00% | – |
| Q4 2021 | $348,000 | +0.9% | 350,000 | 0.0% | 0.00% | – |
| Q3 2021 | $345,000 | -0.6% | 350,000 | 0.0% | 0.00% | – |
| Q2 2021 | $347,000 | +2.4% | 350,000 | 0.0% | 0.00% | – |
| Q1 2021 | $339,000 | +2.7% | 350,000 | 0.0% | 0.00% | – |
| Q4 2020 | $330,000 | +2.2% | 350,000 | 0.0% | 0.00% | – |
| Q3 2020 | $323,000 | +3.9% | 350,000 | 0.0% | 0.00% | – |
| Q2 2020 | $311,000 | +9.9% | 350,000 | 0.0% | 0.00% | – |
| Q1 2020 | $283,000 | -11.0% | 350,000 | 0.0% | 0.00% | – |
| Q4 2019 | $318,000 | -2.5% | 350,000 | 0.0% | 0.00% | – |
| Q3 2019 | $326,000 | -51.0% | 350,000 | -50.0% | 0.00% | – |
| Q2 2019 | $665,000 | – | 700,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wellesley Asset Management | 71,162 | $69,799,000 | 4.72% |
| ZAZOVE ASSOCIATES LLC | 27,692,000 | $27,021,000 | 2.38% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 61,727,000 | $60,252,000 | 1.17% |
| SHENKMAN CAPITAL MANAGEMENT INC | 7,637,000 | $7,524,000 | 0.85% |
| NN Investment Partners Holdings N.V. | 38,700,000 | $37,743,000 | 0.30% |
| CAMDEN ASSET MANAGEMENT L P /CA | 5,825,000 | $5,684,000 | 0.18% |
| EDMOND DE ROTHSCHILD HOLDING S.A. | 4,479,000 | $4,384,000 | 0.16% |
| Lombard Odier Asset Management (Europe) Ltd | 2,005,000 | $1,905,000 | 0.16% |
| PRUDENTIAL PLC | 41,809,000 | $40,973,000 | 0.12% |
| Calamos Advisors LLC | 22,303,000 | $21,829,000 | 0.12% |